Powered By
Hydrea, generic name hydroxyurea (HU), is a chemotherapy (cytotoxin) that interferes with DNA activity in hematopoietic stem cells and other cells in the body. It is used off-label for MPNs but is in common use and recognized in the NCCN guidelines as one of the first-line choices for PV/ET. The other first-line option is one of the pegylated interferons, Pegasys or Besremi. The IFNs are immune modulating therapies that allow the body to more selectively target the mutated blood progenitor cells. The IFNs are potentially disease modifying, reducing risk of progression. HU is not. HU is faster acting but the long term success is better with the IFNs for some.
500mg (1 cap) is a common starting dose. If initiating HU, the protocol is to have a CBC every two weeks until stable. Regular CMPs are also needed to monitor for potential impact on kidneys/liver.
We are all different in how we respond to these drugs. SOme tolerate HU OK and can benefit. Others do not. I am one of the latter. I have done much better on the IFNs. They have been more effective and much easier to tolerate than HU for me.
Since you are considering HU as an option, here is some useful information.
https://www.drugs.com/monograph/hydroxyurea.html
https://www.oralchemoedsheets.com/sheets/Hydrox...
https://ethrombo.blogspot.com/2017/10/taking-ch...
What is Hydrea and how does it treat MPNs?
Hydrea (Hydroxyurea) is a chemotherapy medication commonly used to treat myeloproliferative neoplasms. It works by decreasing the number of blood cells that your bone marrow produces, affecting all types of blood cells.
For MPNs, Hydrea is typically taken at low doses in oral Show Full Answer
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
